HSP90β chaperoning SMURF1-mediated LATS proteasomal degradation in the regulation of bone formation

  • Cell Signal. 2023 Feb:102:110523. doi: 10.1016/j.cellsig.2022.110523.
Meiyu Qu  1 Ying Gong  2 Yuyang Jin  3 Ruibo Gao  4 Qiangqiang He  4 Yana Xu  1 Tingyu Shen  4 Liu Mei  5 Chengyun Xu  4 Musaddique Hussain  4 Muhammad Qasim Barkat  4 Ximei Wu  6
Affiliations
  • 1. Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China,; Department of Orthopaedics, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
  • 2. Department of Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. Electronic address: [email protected].
  • 3. Shanghai Luyi Cell Biotech Co., Ltd, Jiading District, Shanghai 201821, China.
  • 4. Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • 5. Department of Biochemistry and Biophysics, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA.
  • 6. Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou 310058, China,; Department of Orthopaedics, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China. Electronic address: [email protected].
Abstract

Heat shock protein 90 (HSP90) molecular chaperone is responsible for the stabilization and biological activity of a diverse set of client proteins. We have previously demonstrated that inhibition of HSP90 by 17-Demethoxy-17-allyaminogeldanmycin (17-AAG) not only reverses the glucocorticoid-induced bone loss but also enhances the basal level of bone mass in mice. Here, we investigate the potential mechanism underlying HSP90-associated osteoblast differentiation and bone formation. Knockdown of HSP90β but not HSP90α or inhibition of HSP90 by 17-AAG or NVP-BEP800 negates the protein levels of large tumor suppressor (LATS), the core kinases of Hippo signaling, resulting in the inactivation of LATS and activation of Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), in the enhancement of osteoblastic differentiation. In contrast, genetic ablation of Lats1 in mesenchymal stem cells is sufficient to abolish the HSP90 inhibition-induced osteoblastic differentiation and bone formation. Mechanistically, HSP90β but not HSP90α chaperones and prevents the SMAD specific E3 ubiquitin protein Ligase 1 (SMURF1)-mediated and ubiquitination-dependent LATS protein proteasomal degradation, whereas 17-AAG abolishes these effects of HSP90β. Thus, these results uncover the HSP90β chaperoning SMURF1-mediated LATS protein proteasomal degradation and the subsequent YAP/TAZ activation as a hitherto uncharacterized mechanism controlling osteoblastic differentiation and bone formation.

Keywords
17-AAG; HSP90β; LATS; Osteoblast; SMURF1.
Products